Long-Read Sequencing Market (2026-2036)

The growth of this market is mainly driven by the ability of long-read sequencing to resolve structural variants, repeat expansions, and complex genomic regions that short-read sequencing cannot, the increasing use of long reads in rare disease diagnosis and clinical genomics, the expansion of population genomics and newborn sequencing programs, and the declining cost and rising throughput of long-read platforms. In addition, the growing adoption of full-length transcriptomics and native methylation analysis, the expansion of long-read sequencing into infectious disease, biopharmaceutical, and applied markets, the availability of benchtop and IVD-marked systems, and the entry of new technology providers are further supporting the growth of this market.

The Long-Read Sequencing Market, also referred to as the third-generation sequencing, single-molecule sequencing, or long-read DNA and RNA sequencing market, comprises the instruments, consumables, services, and software used to sequence DNA and RNA molecules thousands to millions of bases long in a single read. The market includes nanopore sequencing, which reads nucleic acids as they pass through protein nanopores; single-molecule real-time (SMRT) sequencing, including high-fidelity (HiFi) sequencing; and synthetic and mapped long-read technologies that reconstruct long-range genomic information on short-read platforms. It covers sequencing instruments, flow cells and SMRT Cells, sequencing reagents, library preparation and high-molecular-weight DNA extraction kits, target enrichment panels, sequencing services, and bioinformatics software. These technologies enable complete genome assembly, structural variant and repeat expansion detection, full-length transcript analysis, and direct detection of DNA and RNA modifications. The market ecosystem extends from sample preparation and reagent suppliers to platform manufacturers, sequencing service providers, bioinformatics providers, diagnostics partners, and academic, clinical, pharmaceutical, and applied end users.

The market is experiencing strong growth as researchers and clinicians increasingly recognize that a significant share of medically relevant genetic variation lies in regions that short-read sequencing cannot reliably resolve, including structural variants, segmental duplications, tandem repeats, and complex genes involved in repeat expansion disorders and drug metabolism. Long reads can span these regions in a single molecule, phase variants across entire genes and chromosomes, and detect methylation directly without chemical conversion, providing a more complete view of the genome than short reads alone. As a result, long-read sequencing is moving from a specialized research tool toward a mainstream complement to short-read sequencing in genomics laboratories, genome centers, and clinical programs.

The two established platform providers reflect the changing structure of demand. Oxford Nanopore Technologies reported 2025 revenue of GBP 223.9 million, up 24.2% at constant currency, with clinical revenue up 59.9% to GBP 29.8 million, BioPharma revenue up 30.4% to GBP 18.1 million, Applied Industrial revenue up 27.2% to GBP 27.5 million, and PromethION revenue up 43.1% to GBP 110.6 million. The company also registered its first in vitro diagnostic product, GridION Dx, with CE and UKCA marking, launched the AmPORE-TB assay for drug-resistant tuberculosis with bioMérieux, and formed a partnership with Cepheid for automated infectious disease sequencing, while guiding to constant currency revenue growth of 21% to 25% in 2026 and adjusted EBITDA breakeven in 2027. PacBio reported 2025 revenue of about USD 160.0 million, up 4%, with record consumables revenue of about USD 81.9 million, up from USD 70.3 million, and placements of 61 Revio and 140 Vega systems, and expects 2026 revenue of USD 155 million to USD 165 million. The record level of PacBio consumables revenue, alongside a decline in instrument revenue to about USD 53.8 million from USD 65.8 million, indicates that growth is increasingly driven by utilization of the installed base rather than by new capital purchases.

Clinical and population genomics programs are adding a new and more durable layer of demand to a market historically dominated by academic research. In September 2025, Genomics England awarded contracts worth about GBP 3.49 million for long-read whole genome sequencing of at least 2,000 samples across two long-read technologies, Oxford Nanopore and PacBio, for the Babies in Focus cohort within the Generation Study, which is assessing whole genome sequencing for newborn screening and rare condition diagnosis. Oxford Nanopore reported clinical revenue growth of 59.9% in 2025 and 35% in H1 2026, and PacBio cited meaningful traction across a range of clinical sequencing applications, with increasing real-world evidence expected to support growth in 2026 and beyond. Clinical laboratories are also offering long-read testing as a service, as reflected in Azenta Life Sciences becoming the first commercial provider to receive regulatory approval to offer a clinical long-read whole genome sequencing test in the U.S. in October 2024, performed on PacBio Revio systems in its CLIA-certified and CAP-accredited laboratory.

The competitive landscape is broadening as short-read and Chinese sequencing companies enter the long-read and long-range segment. In March 2026, MGI Tech acquired CycloneSEQ, which commercializes nanopore long-read sequencing on its G100-ER and G400-ER platforms, bringing long-read capability alongside its DNBSEQ short-read portfolio. Qitan Technology launched the QPinnacle2 high-throughput nanopore sequencer in 2025, with two chips producing 400 Gb each, completing a low-, medium-, and high-throughput portfolio alongside its QNome and QPursue systems. Illumina has commercialized its proximity mapped read technology as the TruPath Genome solution, which provides ultra-long phasing and improved detection of large structural rearrangements without traditional library preparation. These developments are increasing the choice of platforms available to laboratories and intensifying competition on cost, accuracy, and workflow simplicity.

At the same time, geopolitical factors are reshaping regional demand. Oxford Nanopore reported that its revenue declined 16% in China and 14% in the Middle East in H1 2026, while revenue excluding these markets grew 16% at constant currency and revenue in Europe, the Middle East, Africa, and India (EMEAI) grew 23% at constant currency. Chinese laboratories are increasingly adopting domestic long-read platforms such as CycloneSEQ and Qitan Technology systems, creating a more regionalized market in which international providers are focusing growth efforts on Europe, North America, and other regions.

Applications are also broadening well beyond human genomics. Long-read sequencing is used for microbial and viral genomics, infectious disease surveillance, metagenomics, plant and animal genomics, food safety, and biopharmaceutical quality control, including the verification of plasmids, viral vectors, mRNA constructs, and cell lines. Oxford Nanopore reported Applied Industrial revenue growth of 27.2% and BioPharma revenue growth of 30.4% in 2025, reflecting the expansion of long-read sequencing into regulated manufacturing and applied testing environments where complete and accurate sequence information is required.